Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674858 | 0.86 | TACR1 (0.39) | TAAR1TACR1AOC3PFKFB3 | |
| SCHEMBL19998093 | 0.85 | HTT (0.39) | TAAR1TACR1GAANPSR1 | |
| SCHEMBL19121042 | 0.74 | TAAR1 (0.49) | TAAR1CASRHDAC4HDAC8SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL5308329 | 0.72 | CASR (0.60) | TAAR1MAOBCASRSLC6A4 | |
| SCHEMBL2758299 | 0.71 | ALDH1A1 (0.45) | ACHETACR1GAANPSR1 | |
| SCHEMBL22861119 | 0.70 | PTGS2 (0.41) | TAAR1CASRSLC6A4 | |
| SCHEMBL19675529 | 0.70 | TAAR1 (0.65) | TAAR1TACR1MAOBCASRSLC6A4 | |
| SCHEMBL13708872 | 0.69 | CASR (0.49) | TAAR1MAOBCASRMAPT | |
| SCHEMBL10442440 | 0.69 | ACHE (0.62) | ACHETAAR1MAOBCASRAOC3 | |
| SCHEMBL99347 | 0.69 | ACHE (0.55) | ACHEGAAMAPTAOC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ACHE 4620/4885TAAR1 412/4885TACR1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.